"By participating in CISCE, Fonterra firmly supports China's efforts to establish an advanced supply chain -- particularly in the area of green agriculture, where we are keen to contribute," said ...

The global small-molecule injectable market is poised for significant growth, with an estimated valuation of USD 65.10 ...

Clinical trials for a revolutionary vaccine to treat acne will be conducted by the National Skin Centre in partnership with ...

Expansion into Emerging Markets with High Prevalence of Chronic Inflammatory Conditions Presenting Lucrative Opportunities ...

In cases involving unpredictable factors, such as most chemical reactions, pharmaceutical activity, and physiological ...

Sanofi inaugurated its $800m healthcare manufacturing facility, Modulus, located in Tuas Biomedical Park to be operational in ...

The biggest threat for European pharmaceutical groups currently comes from the United States. President-elect Donald Trump ...

Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

The microbial therapeutic products market is forecast to grow from USD 17.11 billion in 2022 to USD 30.55 billion by 2030, ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

Diet is increasingly seen as a modifiable risk factor in prostate cancer. Recent studies have shown that ...